Erika Paula R Pizarro, MD
Psychiatry · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 3 carriers
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · Mark David Levine MD Professional Corporation · 165 clinicians in this group
Looking this up.
Plans that list them
15 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pizarro’s office at (855) 501-1004 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
Original Medicare doctor bills
$5,252
Medicare paid this office $5,252 for 11 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 11 | $3,883 | $95 |
Who their Medicare patients are
11 Original Medicare patients in 2024. Average age 62 · 85 and older 0% · Health risk score 0.88. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
The office billed $28,455, Medicare allowed $8,000 and paid $5,252; for 50 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$52,454 in 2024
Medicaid paid $52,454 for 204 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 204 | $52,454 |
| 2024 | 204 | 1 | 26 | $52,454 |
| 2023 | 177 | 1 | 27 | $47,626 |
| 2022 | 304 | 1 | 26 | $85,433 |
| 2021 | 290 | 1 | 34 | $81,493 |
| 2020 | 464 | 1 | 46 | $173,804 |
| 2019 | 470 | 1 | 52 | $132,914 |
| 2018 | 511 | 1 | 52 | $135,510 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 177 | $47,626 |
2022
| Return visit (30+ min) | 304 | $85,433 |
2021
| Return visit (30+ min) | 290 | $81,493 |
2020
| Return visit (30+ min) | 464 | $173,804 |
2019
| Return visit (30+ min) | 470 | $132,914 |
2018
| Return visit (30+ min) | 511 | $135,510 |
Drugs they prescribed that Part D paid
$65,747
Pharmacies billed $65,747 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 583) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
546 generic and 37 brand-name prescriptions · $65,747 in drug cost · 68 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vraylar | 21 | $39,388 | $1,876 |
| Trintellix | 12 | $5,549 | $462 |
| Lisdexamfetamine Dimesylate | 12 | $4,246 | $354 |
| Duloxetine | 40 | $1,382 | $35 |
| Fluvoxamine Maleate | 12 | $754 | $63 |
See all 19 drugs
| Vraylar | 21 | $39,388 | $1,876 |
| Trintellix | 12 | $5,549 | $462 |
| Lisdexamfetamine Dimesylate | 12 | $4,246 | $354 |
| Duloxetine | 40 | $1,382 | $35 |
| Fluvoxamine Maleate | 12 | $754 | $63 |
| Bupropion Xl | 35 | $734 | $21 |
| Quetiapine | 44 | $552 | $13 |
| Gabapentin | 22 | $550 | $25 |
| Dextroamphetamine-Amphetamine | 21 | $494 | $24 |
| Fluoxetine | 28 | $437 | $16 |
| Trazodone | 34 | $390 | $11 |
| Escitalopram | 18 | $283 | $16 |
| Sertraline | 23 | $254 | $11 |
| Lamotrigine | 18 | $192 | $11 |
| Clonazepam | 52 | $188 | $4 |
| Citalopram Hbr | 16 | $115 | $7 |
| Buspirone | 17 | $63 | $4 |
| Lorazepam | 24 | $38 | $2 |
| Alprazolam | 18 | $33 | $2 |
Year by year
| 2024 | 583 | 47 | 0% (0) | 6% | $65,747 |
| 2023 | 346 | 32 | 0% (0) | 5% | $33,800 |
| 2022 | 318 | 32 | 0% (0) | 7% | $24,164 |
| 2021 | 248 | 29 | 0% (0) | None | $11,137 |
| 2020 | 161 | 18 | 0% (0) | None | $9,827 |
| 2019 | 181 | 22 | 0% (0) | 8% | $11,176 |
| 2018 | 168 | 13 | 0% (0) | None | $5,160 |
| 2017 | 150 | 14 | 0% (0) | None | $8,788 |
| 2016 | 57 | None | 0% (0) | None | $6,201 |
| 2014 | 11 | None | 0% (0) | 0% | $101 |
| 2013 | 50 | 12 | 0% (0) | None | $2,377 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Duloxetine | 31 | $3,069 | $99 |
| Quetiapine | 32 | $1,768 | $55 |
| Buspirone | 19 | $1,174 | $62 |
| Venlafaxine Hcl Er | 17 | $841 | $49 |
| Fluvoxamine Maleate | 12 | $531 | $44 |
| Clonazepam | 36 | $455 | $13 |
| Dextroamphetamine-Amphetamine | 16 | $415 | $26 |
| Sertraline | 17 | $285 | $17 |
| Trazodone | 26 | $251 | $10 |
| Escitalopram | 16 | $236 | $15 |
| Gabapentin | 11 | $165 | $15 |
| Alprazolam | 21 | $155 | $7 |
| Citalopram Hbr | 13 | $86 | $7 |
| Lorazepam | 17 | $35 | $2 |
2022: 13 drugs
| Aripiprazole | 12 | $1,439 | $120 |
| Duloxetine | 30 | $1,141 | $38 |
| Dextroamphetamine-Amphetamine | 20 | $1,066 | $53 |
| Fluvoxamine Maleate | 13 | $972 | $75 |
| Temazepam | 17 | $930 | $55 |
| Bupropion Xl | 14 | $563 | $40 |
| Quetiapine | 22 | $539 | $24 |
| Trazodone | 32 | $278 | $9 |
| Escitalopram | 18 | $270 | $15 |
| Clonazepam | 17 | $229 | $13 |
| Sertraline | 19 | $173 | $9 |
| Lorazepam | 18 | $72 | $4 |
| Alprazolam | 14 | $71 | $5 |
2021: 11 drugs
| Aripiprazole | 17 | $1,755 | $103 |
| Duloxetine | 14 | $1,085 | $77 |
| Fluvoxamine Maleate | 12 | $686 | $57 |
| Trazodone | 32 | $601 | $19 |
| Quetiapine | 14 | $355 | $25 |
| Dextroamphetamine-Amphetamine | 11 | $329 | $30 |
| Escitalopram | 15 | $242 | $16 |
| Sertraline | 15 | $147 | $10 |
| Clonazepam | 13 | $92 | $7 |
| Lorazepam | 14 | $44 | $3 |
| Alprazolam | 13 | $33 | $3 |
2020: 6 drugs
| Quetiapine | 12 | $553 | $46 |
| Trazodone | 27 | $541 | $20 |
| Escitalopram | 11 | $201 | $18 |
| Sertraline | 13 | $159 | $12 |
| Clonazepam | 11 | $84 | $8 |
| Alprazolam | 11 | $22 | $2 |
2019: 8 drugs
| Aripiprazole | 11 | $1,608 | $146 |
| Mirtazapine | 13 | $605 | $47 |
| Quetiapine | 14 | $546 | $39 |
| Trazodone | 31 | $533 | $17 |
| Escitalopram | 16 | $138 | $9 |
| Sertraline | 15 | $107 | $7 |
| Clonazepam | 12 | $94 | $8 |
| Alprazolam | 13 | $23 | $2 |
2018: 3 drugs
| Clonazepam | 27 | $257 | $10 |
| Trazodone | 22 | $204 | $9 |
| Escitalopram | 25 | $160 | $6 |
2017: 5 drugs
| Clomipramine | 17 | $4,237 | $249 |
| Duloxetine | 14 | $1,431 | $102 |
| Clonazepam | 43 | $373 | $9 |
| Escitalopram | 18 | $151 | $8 |
| Trazodone | 13 | $75 | $6 |
2016: 1 drug
| Olanzapine | 12 | $138 | $11 |
Money from drug and device companies
$1,667 in 2025
| 2025 | 10 | 67 | None | $1,667 |
| 2024 | 9 | 91 | None | $2,152 |
| 2023 | 8 | 35 | None | $1,005 |
| 2022 | 7 | 24 | None | $460 |
| 2020 | 2 | 4 | None | $111 |
| 2019 | 1 | 4 | None | $90 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Axsome Therapeutics | Auvelity | $357 | 11 payments
|
| Abbvie | Vraylar | $343 | 16 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $252 | 11 payments
|
| Vanda Pharmaceuticals | Fanapt | $248 | 14 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $140 | 5 payments
|
| Otsuka America Pharmaceutical | Rexulti | $116 | 2 payments
|
See all 67 published payments
| Vanda Pharmaceuticals | Meals · 2025-12-19 | Fanapt | $12 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-19 | Caplyta | $19 |
| Axsome Therapeutics | Meals · 2025-12-09 | Auvelity | $35 |
| Axsome Therapeutics | Meals · 2025-12-02 | Auvelity | $35 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-21 | Caplyta | $7 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-20 | Trintellix | $19 |
| Abbvie | Meals · 2025-11-18 | Vraylar | $24 |
| Vanda Pharmaceuticals | Meals · 2025-11-13 | Fanapt | $10 |
| Axsome Therapeutics | Meals · 2025-11-13 | Auvelity | $32 |
| Axsome Therapeutics | Meals · 2025-11-06 | Auvelity | $33 |
| Abbvie | Meals · 2025-10-30 | Vraylar | $11 |
| Vanda Pharmaceuticals | Meals · 2025-10-30 | Fanapt | $14 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-23 | Trintellix | $34 |
| Vanda Pharmaceuticals | Meals · 2025-10-23 | Fanapt | $10 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-10 | Caplyta | $25 |
| Abbvie | Meals · 2025-10-07 | Vraylar | $22 |
| Alkermes | Meals · 2025-10-07 | Aristada | $30 |
| Vanda Pharmaceuticals | Meals · 2025-10-03 | Fanapt | $35 |
| Collegium Pharmaceutical | Meals · 2025-09-30 | Jornay Pm | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-25 | Trintellix | $27 |
| Abbvie | Meals · 2025-09-24 | Vraylar | $33 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-12 | Caplyta | $27 |
| Alkermes | Meals · 2025-09-09 | Aristada | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-08-26 | Abilify Maintena | $22 |
| Axsome Therapeutics | Meals · 2025-08-14 | Auvelity | $34 |
| Abbvie | Meals · 2025-07-29 | Vraylar | $21 |
| Axsome Therapeutics | Meals · 2025-06-17 | Auvelity | $27 |
| Abbvie | Meals · 2025-06-12 | Vraylar | $21 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-12 | Caplyta | $24 |
| Biogen | Meals · 2025-06-05 | Zurzuvae | $25 |
| Vanda Pharmaceuticals | Meals · 2025-06-05 | Fanapt | $8 |
| Vanda Pharmaceuticals | Meals · 2025-06-05 | Fanapt | $8 |
| Lundbeck | Meals · 2025-06-04 | Rexulti | $29 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-22 | Trintellix | $37 |
| Vanda Pharmaceuticals | Meals · 2025-05-22 | Fanapt | $24 |
| Axsome Therapeutics | Meals · 2025-05-20 | Auvelity | $31 |
| Vanda Pharmaceuticals | Meals · 2025-05-15 | Fanapt | $18 |
| Abbvie | Meals · 2025-05-14 | Vraylar | $23 |
| Abbvie | Meals · 2025-05-08 | Vraylar | $12 |
| Vanda Pharmaceuticals | Meals · 2025-05-08 | Fanapt | $22 |
| Axsome Therapeutics | Meals · 2025-05-08 | Auvelity | $34 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-02 | Caplyta | $30 |
| Abbvie | Meals · 2025-04-29 | Vraylar | $24 |
| Abbvie | Meals · 2025-04-24 | Vraylar | $13 |
| Abbvie | Meals · 2025-04-17 | Vraylar | $29 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-11 | Caplyta | $33 |
| Vanda Pharmaceuticals | Meals · 2025-04-10 | Fanapt | $6 |
| Vanda Pharmaceuticals | Meals · 2025-04-10 | Fanapt | $12 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-28 | Caplyta | $12 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-27 | Trintellix | $24 |
| Lundbeck | Meals · 2025-03-26 | Rexulti | $24 |
| Abbvie | Meals · 2025-03-20 | Vraylar | $28 |
| Lundbeck | Meals · 2025-03-19 | Rexulti | $28 |
| Vanda Pharmaceuticals | Meals · 2025-03-13 | Fanapt | $31 |
| Axsome Therapeutics | Meals · 2025-03-11 | Auvelity | $33 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-06 | Caplyta | $28 |
| Abbvie | Meals · 2025-03-04 | Vraylar | $21 |
| Abbvie | Meals · 2025-02-27 | Vraylar | $12 |
| Axsome Therapeutics | Meals · 2025-02-27 | Auvelity | $35 |
| Abbvie | Meals · 2025-02-20 | Vraylar | $27 |
| Lundbeck | Meals · 2025-02-19 | Rexulti | $30 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-13 | Caplyta | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-02-12 | Rexulti | $95 |
| Vanda Pharmaceuticals | Meals · 2025-02-07 | Fanapt | $37 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-06 | Caplyta | $24 |
| Abbvie | Meals · 2025-02-04 | Vraylar | $22 |
| Axsome Therapeutics | Meals · 2025-01-30 | Auvelity | $29 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $2,152
| Abbvie | Vraylar | $493 | 23 payments
|
| Axsome Therapeutics | Auvelity | $369 | 11 payments
|
| Noven Therapeutics | Xelstrym | $352 | 23 payments
|
| Alkermes | Aristada | $343 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $177 | 7 payments
|
| Otsuka America Pharmaceutical | Abilify Asimtufii | $147 | 7 payments
|
| Lundbeck | Rexulti | $108 | 4 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $84 | 3 payments
|
| Corium | Azstarys | $80 | 3 payments
|
2023: $1,005
| Abbvie | Vraylar | $540 | 16 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $106 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $98 | 4 payments
|
| Iti | Caplyta | $96 | 4 payments
|
| Alkermes | Aristada | $75 | 3 payments
|
| Lundbeck | Rexulti | $46 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $23 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $21 | 1 payment
|
2022: $460
| Abbvie | Vraylar | $233 | 14 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $87 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $53 | 3 payments
|
| Lundbeck | Rexulti | $26 | 1 payment
|
| Janssen Pharmaceuticals | Spravato | $21 | 1 payment
|
| Bausch Health US | Aplenzin | $20 | 1 payment
|
| Corium | Azstarys | $19 | 1 payment
|
2020: $111
| Takeda Pharmaceuticals U.S.A. | Vyvanse | $87 | 3 payments
|
| Janssen Pharmaceuticals | Spravato | $24 | 1 payment
|
2019: $90
| Shire North American Group | Vyvanse | $90 | 4 payments
|
Professional record
- NPI
- 1619238417
- Licence
- PA MD456425
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 3835 N Freeway Blvd Ste 100, Sacramento, CA, 95834
- NPI first listed
- 2012-06-07
- NPI last updated
- 2026-04-29
- NPI record certified
- 2026-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 999 Baker Way Ste 150, San Mateo, CA, 94404